SANUWAVE Health (OTCMKTS:SNWV) is a medical technology company specializing in non‐invasive regenerative shockwave therapy. The company’s core focus is the development and commercialization of Focused Shock Wave Therapy (FSWT) devices designed to accelerate tissue repair and provide pain relief for patients suffering from chronic wounds and musculoskeletal conditions. Utilizing patented acoustic wave technology, SANUWAVE’s platforms deliver pulsed acoustic energy to targeted areas, promoting neovascularization and tissue regeneration without the need for surgery.
The company’s flagship product, dermaPACE®, is engineered to treat chronic wound conditions such as diabetic foot ulcers and venous leg ulcers. dermaPACE® has received 510(k) clearance from the U.S. Food and Drug Administration and carries CE Mark approval for use in Europe. In addition to wound care, SANUWAVE offers orthoPACE®, which targets orthopedic injuries including plantar fasciitis and soft tissue tendinopathies. Both systems are designed for use in outpatient settings, wound care centers and specialty clinics, offering a non‐pharmacological option for patients unresponsive to standard therapies.
SANUWAVE Health maintains a global distribution network spanning North America, Europe, Asia and Latin America, partnering with medical device distributors, wound care specialists and healthcare institutions. The company continues to expand its market reach through strategic collaborations and clinical studies aimed at broadening the therapeutic applications of its FSWT technology. SANUWAVE also holds a growing intellectual property portfolio covering key aspects of its shockwave delivery platforms and treatment protocols.
Founded in the mid‐2000s and headquartered in Alpharetta, Georgia, SANUWAVE has evolved under the leadership of Dr. Gary S. Jenkins, who serves as Chief Executive Officer and President. Dr. Jenkins, a pioneer in acoustical wave research, has guided the company’s transition from R&D to commercial operations. SANUWAVE remains committed to advancing non‐invasive regenerative medicine solutions that improve patient outcomes and reduce healthcare costs.
